Navigation Links
CoreValve Successfully Treats the First Pacific Rim Patients with Its ReValving System for Percutaneous Aortic Valve Replacement : Australia/New Zealand Regulatory-Cleared Evaluation Registry is Expected to Lead to Market Clearance for These Countries

CoreValve ( announced today that an Australia/New Zealand-focused clinical evaluation of its proprietary percutaneous ReValving System, which features a porcine pericardium valve mounted in a self-expanding frame, was initiated last week.

IRVINE, Calif. (Business Wire EON) August 28, 2008 -- The first four procedures using the CoreValve ReValving System were performed in two days by John Ormiston, M.D., Medical Director at Mercy Hospital in Auckland, New Zealand.

"With the CoreValve ReValving system, a new heart valve can be implanted from a small hole made in the groin, and therefore there is no need for major surgery or an incision in the chest," said Dr. Ormiston. "Patient recovery is much quicker, and the procedure can be performed on patients who are at very high risk, or not candidates, for traditional heart valve surgery. This procedure is truly a revolution in cardiology and is part of the trend toward less-invasive treatment," added Dr. Ormiston. "Currently, percutaneous aortic valve replacement (PAVR) is used for carefully selected high-risk patients only. But if good long-term results are sustained, PAVR may substitute for traditional aortic valve replacement surgery in more patients."

"We are gratified by the continued clinical acceptance of our ReValving technology, the smallest percutaneous system currently available. The extensive clinical experience we have in Europe, where we are the market leader, will greatly facilitate the introduction of our revolutionary technology in the Pacific Rim and other regions throughout the world. Additionally, several scientific presentations regarding our technology and clinical data are scheduled at the upcoming European Society of Cardiology (ESC) meeting in Munich, Germany," said Daniel Lemaitre, CoreValve's President and Chief Executive Officer.

About CoreValve

CoreValve, Inc., is headquartered in Irvine, Calif. Its proprietary ReValving System allows both percutaneous aortic valve replacement (PAVR) and transapical aortic valve replacement (TAVR) and is intended to provide an alternative to open-heart surgery. The ReValving System procedures are performed on the beating heart without cardiac assistance or rapid pacing, and may result in less trauma to the patient. This technology may also offer substantial cost-savings to the healthcare system. The catheter-based technology includes a proprietary framed/self-expanding tissue heart valve that is specifically designed and engineered for transcatheter delivery. For more information about CoreValve, visit the Company's Web site at

(Caution: the CoreValve ReValving System will not be available in the USA for clinical trials or for sale until further notice.)

Read the full story at

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
2. Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period
3. TopoTarget Successfully Buys Back Full Control of Belinostat
4. Bayer HealthCare Affiliate MEDRAD Successfully Completes Tender Offer for Shares of Possis Medical; Announces Subsequent Offering Period
5. SBT Acquisition Inc. Successfully Completes Tender Offer for Shares of Lifecore Biomedical, Inc.
6. Phase I Safety and Tolerability Study With EVT 302 Successfully Completed
7. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
8. Life on Mars pregnancy test successfully launched
9. EpiStem Successfully Complete First Year of Mucositis Tests for NIH Biodefence Programme
10. Oncolytics Biotech Inc. Treats 200th Cancer Patient in Clinical Studies with REOLYSIN(R)
11. New Study Reports That Ablative Therapy With HALO360 Device Effectively Treats Highest-Risk Category of Barretts Esophagus
Post Your Comments:
Related Image:
 CoreValve Successfully Treats the First Pacific Rim Patients with Its ReValving System for Percutaneous Aortic Valve Replacement :  Australia/New Zealand Regulatory-Cleared Evaluation Registry is Expected to Lead to Market Clearance for These Countries 
(Date:11/25/2015)... Mass. , Nov. 25, 2015 Harvard ... biotechnology company developing bioengineered organ implants for life-threatening conditions, ... present at the LD Micro "Main Event" investor conference ... The presentation will be webcast live and posted for ... be available at the conference for one-on-one meetings on ...
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris ... that its business and prospects remain fundamentally strong ... Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation to ... completion following review of the final interim efficacy ... 2 Primary Endpoint in men with heavily pretreated ...
(Date:11/25/2015)... , Nov. 25, 2015 Orexigen® Therapeutics, ... will participate in a fireside chat discussion at the ... New York . The discussion is scheduled for ... .  A replay will be available ... Contact:McDavid Stilwell  , Julie NormartVP, Corporate Communications and ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... company uBiome, were featured on AngelList early in their initial angel funding process. ... AngelList syndicate for individuals looking to make early stage investments in the microbiome ...
Breaking Biology Technology:
(Date:11/10/2015)... , Nov. 10, 2015  In this ... the basis of product, type, application, disease ... in this report are consumables, services, software. ... are safety biomarkers, efficacy biomarkers, and validation ... report are diagnostics development, drug discovery and ...
(Date:11/4/2015)... , November 4, 2015 ... new market report published by Transparency Market Research "Home Security ... Trends and Forecast 2015 - 2022", the global home security ... 30.3 bn by 2022. The market is estimated to ... period from 2015 to 2022. Rising security needs among ...
(Date:10/29/2015)... -- Daon, a global leader in mobile biometric authentication ... version of its IdentityX Platform , IdentityX v4.0. ... have already installed IdentityX v4.0 and are seeing ... UAF certified server component as an option and ... These customers include some of the largest and most ...
Breaking Biology News(10 mins):